Miscellaneous News

EDITORIAL: COVID 19 AND NEUROLOGY – Turkish Neurological Society


In order to obtain data on the frequency and characteristics of neurological symptoms of COVID-19 disease in Turkey, multicenter TNS-COVID-19 Registry was created and it started data retrieval. The review prepared by the TNS-COVID-19 Commission to raise awareness and knowledge about the neurological effects of COVID-19 for neurologists and other disciplines and the effects of COVID-19 pandemic on the monitoring and treatment of neurological diseases, and the management of this process was published in the Turkish Journal of Neurology.

Online stakeholder survey into the (re-)use and re-use of health data in the light of the GDPR


The study is funded by the European Commission and the first results will be used as input for a meeting of Ministries of Health in the EU in July 2020 under the current German EU Presidency, and addressing the future governance for primary and secondary use of health data, also in light of the current COVID-19 pandemic.

The survey will be open until Thursday 9 July 2020 midnight and via the following link:

PAE Survey on Covid-19 and Chronic Pain – Updates!


The first results were presented to PAE members at the PAE General Assembly. You can see them here. The complete analysis and comparison with other surveys will be done in the weeks to come.

The complete outcome will be available on the PAE website. Stay tuned!

WHO: Global collaboration to accelerate new COVID-19 health technologies


Global health actors, private sector partners and other stakeholders are launching a landmark collaboration to accelerate the development, production and equitable global access to new COVID-19 essential health technologies.

COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes


Chloroquine and hydroxychloroquine, two medicines currently authorised for malaria and certain autoimmune diseases, are being investigated worldwide for their potential to treat coronavirus disease (COVID-19). However, efficacy in treating COVID-19 is yet to be shown in studies.

Update on treatments and vaccines against COVID-19 under development


Supporting the rapid development and approval of effective and safe treatments for and vaccines against COVID-19 is EMA’s top priority to help save lives during the pandemic. 

EMA statement on ibuprofen and COVID-19


There is currently no scientific evidence establishing a link between ibuprofen and worsening of COVID‑19. EMA is monitoring the situation closely and will review any new information that becomes available on this issue in the context of the pandemic.